Search research articles
Contact Us
Filters
Showing results (71-80 of 92) with videos related to
Page
of 10
Sort By:
Expert Opinion on Drug Metabolism & Toxicology
|
October 14, 2025
SARS-CoV-2 vaccination and plasma levels of psychotropic agents: a prospective cohort study
Stefano Ferrea, Nazar Kuzo, Giancarlo Giupponi, et al.
Neuropsychiatric Disease and Treatment
|
May 8, 2018
Antidopaminergic medication in healthy subjects provokes subjective and objective mental impairments tightly correlated with perturbation of biogenic monoamine metabolism and prolactin secretion
Tanja Veselinović, Ingo Vernaleken, Paul Cumming, et al.
Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology
|
January 21, 2020
Plasma Risperidone-related Measures in Children and Adolescents with Oppositional Defiant/Conduct Disorders
Daria Piacentino, Georgios D Kotzalidis, Georgios Schoretsanitis, et al.
Journal of Clinical Psychopharmacology
|
November 5, 2016
Pharmacokinetic Drug-Drug Interactions of Mood Stabilizers and Risperidone in Patients Under Combined Treatment
Georgios Schoretsanitis, Ekkehard Haen, Gerhard Gründer, et al.
European Journal of Clinical Pharmacology
|
April 2, 2010
Serum concentrations of paliperidone versus risperidone and clinical effects
Yasmin Nazirizadeh, Friederike Vogel, Wolfgang Bader, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry
|
March 18, 2017
Pharmacokinetic considerations in antipsychotic augmentation strategies: How to combine risperidone with low-potency antipsychotics
Michael Paulzen, Georgios Schoretsanitis, Benedikt Stegmann, et al.
European Journal of Clinical Pharmacology
|
July 5, 2016
Pharmacokinetic patterns of risperidone-associated adverse drug reactions
Georgios Schoretsanitis, Benedikt Stegmann, Christoph Hiemke, et al.
Expert Opinion on Drug Metabolism & Toxicology
|
February 18, 2025
The impact of menstrual cycle on the pharmacokinetics of antiseizure medications and lithium: a systematic review and meta-analysis
Maximilian Gillessen, Chiara Theresa Schmidt, Kristina M Deligiannidis, et al.
International Clinical Psychopharmacology
|
May 12, 2016
Risperidone-induced extrapyramidal side effects: is the need for anticholinergics the consequence of high plasma concentrations?
Georgios Schoretsanitis, Ekkehard Haen, Christoph Hiemke, et al.
Journal of Clinical Psychopharmacology
|
November 6, 2019
Dopamine D2 Receptor Occupancy Estimated From Plasma Concentrations of Four Different Antipsychotics and the Subjective Experience of Physical and Mental Well-Being in Schizophrenia: Results From the Randomized NeSSy Trial
Tanja Veselinović, Martin Scharpenberg, Martin Heinze, et al.
Page
of 10
Search research articles
Search
Showing results (71-80 of 92) with videos related to
Sort By:
Page
of 10
Expert Opinion on Drug Metabolism & Toxicology
|
October 14, 2025
SARS-CoV-2 vaccination and plasma levels of psychotropic agents: a prospective cohort study
Stefano Ferrea, Nazar Kuzo, Giancarlo Giupponi, et al.
Neuropsychiatric Disease and Treatment
|
May 8, 2018
Antidopaminergic medication in healthy subjects provokes subjective and objective mental impairments tightly correlated with perturbation of biogenic monoamine metabolism and prolactin secretion
Tanja Veselinović, Ingo Vernaleken, Paul Cumming, et al.
Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology
|
January 21, 2020
Plasma Risperidone-related Measures in Children and Adolescents with Oppositional Defiant/Conduct Disorders
Daria Piacentino, Georgios D Kotzalidis, Georgios Schoretsanitis, et al.
Journal of Clinical Psychopharmacology
|
November 5, 2016
Pharmacokinetic Drug-Drug Interactions of Mood Stabilizers and Risperidone in Patients Under Combined Treatment
Georgios Schoretsanitis, Ekkehard Haen, Gerhard Gründer, et al.
European Journal of Clinical Pharmacology
|
April 2, 2010
Serum concentrations of paliperidone versus risperidone and clinical effects
Yasmin Nazirizadeh, Friederike Vogel, Wolfgang Bader, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry
|
March 18, 2017
Pharmacokinetic considerations in antipsychotic augmentation strategies: How to combine risperidone with low-potency antipsychotics
Michael Paulzen, Georgios Schoretsanitis, Benedikt Stegmann, et al.
European Journal of Clinical Pharmacology
|
July 5, 2016
Pharmacokinetic patterns of risperidone-associated adverse drug reactions
Georgios Schoretsanitis, Benedikt Stegmann, Christoph Hiemke, et al.
Expert Opinion on Drug Metabolism & Toxicology
|
February 18, 2025
The impact of menstrual cycle on the pharmacokinetics of antiseizure medications and lithium: a systematic review and meta-analysis
Maximilian Gillessen, Chiara Theresa Schmidt, Kristina M Deligiannidis, et al.
International Clinical Psychopharmacology
|
May 12, 2016
Risperidone-induced extrapyramidal side effects: is the need for anticholinergics the consequence of high plasma concentrations?
Georgios Schoretsanitis, Ekkehard Haen, Christoph Hiemke, et al.
Journal of Clinical Psychopharmacology
|
November 6, 2019
Dopamine D2 Receptor Occupancy Estimated From Plasma Concentrations of Four Different Antipsychotics and the Subjective Experience of Physical and Mental Well-Being in Schizophrenia: Results From the Randomized NeSSy Trial
Tanja Veselinović, Martin Scharpenberg, Martin Heinze, et al.
Page
of 10